Regorafenib Drug Insight and Market Forecast - 2032

This “Regorafenib Drug Insight and Market Forecast - 2032” report provides comprehensive insights about regorafenib for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the regorafenib for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the regorafenib for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the regorafenib market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary

Regorafenib is an oral multi-kinase inhibitor that potently blocks multiple protein kinases involved in tumor angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), metastasis (VEGFR3, PDGFR, FGFR) and tumor immunity (CSF1R). It is an inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.

Regorafenib is the first-choice treatment for rGBM according to Italian Association of Medical Oncology guidelines; regorafenib has been approved by Italian Medicines Agency (AIFA) for its use in rGBM as of October 2019, while bevacizumab, although approved by FDA, is not recommended by AIFA and EMA.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the regorafenib description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on regorafenib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the regorafenib research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around regorafenib.
• The report contains forecasted sales of regorafenib for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for regorafenib in GBM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Regorafenib Analytical Perspective

In-depth Regorafenib Market Assessment

This report provides a detailed market assessment of regorafenib for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Regorafenib Clinical Assessment

The report provides the clinical trials information of regorafenib for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence regorafenib dominance.
• Other emerging products for GBM are expected to give tough market competition to regorafenib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of regorafenib in GBM.
• This in-depth analysis of the forecasted sales data of regorafenib from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the regorafenib in GBM.

Key Questions

• What is the product type, route of administration and mechanism of action of regorafenib?
• What is the clinical trial status of the study related to regorafenib in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the regorafenib development?
• What are the key designations that have been granted to regorafenib for GBM?
• What is the forecasted market scenario of regorafenib for GBM?
• What are the forecasted sales of regorafenib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to regorafenib for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

This product will be delivered within 2 business days.